Document is current
Any future updates will be listed below
-
Authors
Pees, Anna https://orcid.org/0000-0001-8207-3358
Grotegerd, Ann-Kathrin https://orcid.org/0009-0002-2717-0723
Bleher, Daniel https://orcid.org/0000-0002-2216-2524
Herfert, Kristina https://orcid.org/0000-0003-0231-7717
Vasdev, Neil https://orcid.org/0000-0002-2087-5125
-
Funding
Funding for this research was provided by:
Michael J. Fox Foundation for Parkinson's Research (MJFF-024348)
Werner Siemens-Stiftung (Werner Siemens-Stiftung)
Centre for Addiction and Mental Health Foundation (Discovery fund and womenmind)
Azrieli Foundation (Azrieli Foundation)
Canada Research Chairs (Tier 1)
- License Information
-
More Information
Article History
Received: 18 August 2025
Accepted: 17 November 2025
First Online: 21 January 2026
Declarations
:
: This article does not contain any studies with human participants or animals performed by any of the authors.
: Not applicable.
: All authors read and approved the final manuscript for publication.
: N.V. is a co-founder of MedChem Imaging, Inc. K.H. has been involved in collaborative research with MODAG GmbH on the development and evaluation of [¹¹C]MODAG-005. K.H. is also listed as an inventor on the following patent applications: (1) Novel compounds for the diagnosis , treatment and prevention of diseases associated , US2023067910A1, filed by MODAG GmbH (published March 2, 2023); and (2) 2-Styrylbenzothiazole derivatives as α-synuclein binding compounds , EP4438597A1, filed by the University of Tuebingen, Medical Faculty (published October 2, 2024). The authors have no other relevant financial or non-financial interests to disclose.
: In addition to AI assisted copy editing, as defined by the journal guidelines, ChatGPT (OpenAI, Version 4o) was used for literature summarization. All content was critically reviewed and verified by the authors. The authors confirm that the edits reflect their original work, and accept human accountability for the final version.
: Not Applicable.
